VCV002976127.2 - ClinVar

NM_000153.4(GALC):c.1859G>C (p.Gly620Ala)

Germline

Classification

The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.

(2)

Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.

Conflicting classifications of pathogenicity
Likely pathogenic(1); Uncertain significance(1)

criteria provided, conflicting classifications

Somatic

No data submitted for somatic clinical impact

Somatic

No data submitted for oncogenicity

Variant Details

Identifiers

NM_000153.4(GALC):c.1859G>C (p.Gly620Ala)

Variation ID: 2976127 Accession: VCV002976127.2

Type and length

single nucleotide variant, 1 bp

Location

Cytogenetic: 14q31.3 14: 87939957 (GRCh38) [ NCBI UCSC ] 14: 88406301 (GRCh37) [ NCBI UCSC ]

Timeline in ClinVar

	First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.	Last submission Help The date of the most recent submission for each type of classification for this variant.	Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline	Feb 29, 2024	Dec 14, 2024	Oct 30, 2024

HGVS

Nucleotide	Protein	Molecular consequence
NM_000153.4:c.1859G>C MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.	NP_000144.2:p.Gly620Ala	missense
NM_001201401.2:c.1790G>C	NP_001188330.1:p.Gly597Ala	missense
NM_001201402.2:c.1781G>C	NP_001188331.1:p.Gly594Ala	missense
NM_001424071.1:c.1691G>C	NP_001411000.1:p.Gly564Ala	missense
NM_001424072.1:c.1691G>C	NP_001411001.1:p.Gly564Ala	missense
NM_001424073.1:c.1691G>C	NP_001411002.1:p.Gly564Ala	missense
NM_001424074.1:c.1511G>C	NP_001411003.1:p.Gly504Ala	missense
NM_001424075.1:c.1511G>C	NP_001411004.1:p.Gly504Ala	missense
NM_001424076.1:c.1226G>C	NP_001411005.1:p.Gly409Ala	missense
NM_001424077.1:c.1226G>C	NP_001411006.1:p.Gly409Ala	missense
NR_187582.1:n.1696G>C		non-coding transcript variant
NC_000014.9:g.87939957C>G
NC_000014.8:g.88406301C>G
NG_011853.3:g.58607G>C

... more HGVS ... less HGVS

Protein change

G564A, G594A, G597A, G620A, G409A, G504A

Other names

Canonical SPDI

NC_000014.9:87939956:C:G

Functional consequence Help The effect of the variant on RNA or protein function, based on experimental evidence from submitters.

Global minor allele frequency (GMAF) Help The global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.

Allele frequency Help The frequency of the allele represented by this VCV record.

Links

VarSome

Genes

Gene	OMIM	ClinGen Gene Dosage Sensitivity Curation		Variation Viewer Help Links to Variation Viewer, a genome browser to view variation data from NCBI databases.	Related variants
Gene	OMIM	HI score Help The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team.	TS score Help The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team.		Within gene Help The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants.	All Help The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene.
GALC		-	-	GRCh38 GRCh37	1333	1446

Conditions - Germline

Condition Help The condition for this variant-condition (RCV) record in ClinVar.	Classification Help The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions)	Review status Help The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status.	Last evaluated Help The most recent date that a submitter evaluated this variant for the condition.	Variation/condition record Help The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page.
not specified	Uncertain significance (1)	criteria provided, single submitter	Oct 30, 2024	RCV004801411.1
Galactosylceramide beta-galactosidase deficiency	Likely pathogenic (1)	criteria provided, single submitter	Mar 7, 2023	RCV003836277.2

Submissions - Germline

Classification Help The submitted germline classification for each SCV record. (Last evaluated)	Review status Help Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria)	Condition Help The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant.	Submitter Help The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar.	More information Help This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter.
Likely pathogenic (Mar 07, 2023)	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015)) Method: clinical testing	Galactosylceramide beta-galactosidase deficiency Affected status: unknown Allele origin: germline	Labcorp Genetics (formerly Invitae), Labcorp Accession: SCV004634902.1 First in ClinVar: Feb 28, 2024 Last updated: Feb 28, 2024	Publications: PubMed (1) PubMed: 31240153 Comment: This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 620 of the GALC protein (p.Gly620Ala). … (more) This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 620 of the GALC protein (p.Gly620Ala). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Gly620 amino acid residue in GALC. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 31240153). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALC protein function. This variant has not been reported in the literature in individuals affected with GALC-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0009%). (less)
Uncertain significance (Oct 30, 2024)	criteria provided, single submitter (LabCorp Variant Classification Summary - May 2015) Method: clinical testing	not specified Affected status: unknown Allele origin: germline	Women's Health and Genetics/Laboratory Corporation of America, LabCorp Accession: SCV005423321.1 First in ClinVar: Dec 14, 2024 Last updated: Dec 14, 2024	Comment: Variant summary: GALC c.1859G>C (p.Gly620Ala) results in a non-conservative amino acid change located in the Glycosyl hydrolase family 59, C-terminal lectin domain (IPR049162) of the … (more) Variant summary: GALC c.1859G>C (p.Gly620Ala) results in a non-conservative amino acid change located in the Glycosyl hydrolase family 59, C-terminal lectin domain (IPR049162) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 248764 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.1859G>C in individuals affected with Krabbe Disease and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 2976127). Based on the evidence outlined above, the variant was classified as uncertain significance. (less)

Comment:

This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 620 of the GALC protein (p.Gly620Ala). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Gly620 amino acid residue in GALC. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 31240153). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALC protein function. This variant has not been reported in the literature in individuals affected with GALC-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0009%).

Comment:

Variant summary: GALC c.1859G>C (p.Gly620Ala) results in a non-conservative amino acid change located in the Glycosyl hydrolase family 59, C-terminal lectin domain (IPR049162) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 248764 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.1859G>C in individuals affected with Krabbe Disease and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 2976127). Based on the evidence outlined above, the variant was classified as uncertain significance.

Germline Functional Evidence

There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar.

Comment:

Citations for germline classification of this variant

Title	Author	Journal	Year	Link
Genotype and phenotype classification of 29 patients affected by Krabbe disease.	Madsen AMH	JIMD reports	2019	PMID: 31240153

Text-mined citations for this variant ...

Record last updated Dec 15, 2024

ClinVar Genomic variation as it relates to human health

NM_000153.4(GALC):c.1859G>C (p.Gly620Ala)

Variant Details

Genes

Conditions - Germline

Submissions - Germline

Germline Functional Evidence

Citations for germline classification of this variant

Text-mined citations for this variant ...